ClearLight Diagnostics Announces the Appointment of Laurie Goodman, PhD to Its Executive Staff
SUNNYVALE, Calif., Sept. 14, 2016 /PRNewswire/ -- ClearLight Diagnostics, LLC (ClearLight), a developer of next generation tissue processing and 3D imaging platforms for research and diagnostic applications, announced today the appointment of Laurie Goodman, PhD as Chief Scientific Officer. Dr. Goodman will serve as the Company's principal scientific officer and will be responsible for the design and execution of ClearLight's scientific development programs.
"Laurie brings a tremendous amount of cancer diagnostics experience to ClearLight, not only from developing and commercializing FDA approved diagnostic technologies and tests, but also from the perspective of clinical development and medical affairs, and understanding the value of bringing new technologies to the research and diagnostics markets," said Sarah McCurdy, Chief Executive Officer of ClearLight. "It's an honor to appoint Laurie to this position, and I look forward to the valuable contribution she will make to ClearLight as we move forward to further develop our 3D, next generation tissue processing and 3D imaging platforms."
Dr. Goodman has served as a consultant to ClearLight since August 2015. Prior to joining ClearLight, she served as Senior Director of Medical Affairs at Biodesix, and held positions of increasing responsibility at Affymetrix, Monogram Biosciences, and Lynx Therapeutics.
Dr. Goodman holds a B.S. in Biology from Arizona State University and a doctorate in Cell and Molecular Biology from University of California, Berkeley. She completed a postdoctoral fellowship at Genentech.
"ClearLight is committed to initiating and executing research and development, as well as clinical development plans that will help to identify key biomarkers of response and resistance to drug therapy," said Dr. Goodman. "I am honored to be part of an exemplary group of individuals who are committed to develop and commercialize the next generation clinical tissue analysis platform."
ClearLight is developing a tissue processing platform based on the CLARITY lipid-clearing technique developed by Karl Deisseroth MD and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. This process produces fully assembled intact tissue, which is optically transparent and permeable to macromolecules, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy), will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology. Visit www.clearlightdx.com.
Contact:
ClearLight
Sarah McCurdy
Email
928-525-4290
SOURCE ClearLight Diagnostics, LLC
Share this article